logo
logo

Poxel Successfully Raises €17.7 Million in a Capital Increase

May 25, 2020•about 5 years ago

Amount Raised

€17 Million

Description

POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) (“Poxel”, or the “Company”), today announced the successful private placement of 2,358,483 new ordinary shares, each with a nominal value of €0.02 per share (the “New Shares”), reserved to a specified category of investors (the “Reserved Offering”). The gross proceeds of the Reserved Offering are €17,688,622.50 ($19.4 million).

Company Information

Company

About

AccelFoods is an early-stage venture fund investing in consumer products. We partner with entrepreneurs to bring innovative, high-quality food and beverage products to the forefront of the industry and create the next generation of enduring brands. With nearly $40m under management, we are hands-on partners that work tactically with our founders to scale their businesses quickly and smartly. We connect the dots within the broader food & beverage ecosystem to provide unique access, share distinct expertise, and build solid infrastructure.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People